Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
- Written by PR Newswire
![]() |
First-in-Class ERAP1 Inhibitor Enters Clinical Development
Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune...